Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-19
2006-09-19
Wilson, James O. (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C549S064000, C549S070000, C549S083000
Reexamination Certificate
active
07109354
ABSTRACT:
Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula Ior a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4and R7are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.
REFERENCES:
patent: 4510130 (1985-04-01), Platt et al.
patent: 4634783 (1987-01-01), Fujii et al.
patent: 4722890 (1988-02-01), Sanders et al.
patent: 4727064 (1988-02-01), Pitha
patent: 4764604 (1988-08-01), Mueller
patent: 4916219 (1990-04-01), Linhardt et al.
patent: 5024998 (1991-06-01), Bodor
patent: 5268363 (1993-12-01), Nicholson-Weller
patent: 5466811 (1995-11-01), Alexander
patent: 5472939 (1995-12-01), Fearon et al.
patent: 6410587 (2002-06-01), Grainger et al.
patent: 6410733 (2002-06-01), Pastor et al.
patent: 6562840 (2003-05-01), Illig et al.
patent: 0 983 982 (2000-03-01), None
patent: WO 99/20608 (1999-04-01), None
patent: WO 00/47578 (2000-08-01), None
Adachi, H. et al., “Effects of cyclosporine, aspirin, and cobra venom factor on discordant cardiac xenograft survival in rats,”Trans. Proc., Feb. 1987, 19(1), 1145-1148.
Ahrenstedt, Ö., et al., “Enhanced local production of complement components in the small intestines of patients with Crohn's disease,”New Engl. J. Med., 1990, 322, 1345-1349.
Ashworth, R. De B., et al., “Synthetic antimalarials. Part XXXVII. Some N1-p-Chlorophenyl-N2: N4: N5-trialkyldiguanides and other related miscellaneous diguanide types,”J. Chem. Soc., 1949, 475-482.
Badalamente, M.A., et al., “Neuromuscular recovery using calcium protease inhibition after median nerve repair in primates,”Proc. Natl. Acad. Sci. USA, Aug. 1989, 86, 5983-5987.
Biesecker, G., et al., “Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis,”J. Exp. Med., Dec. 1981, 154, 1779-1794.
Biesecker, G., et al., “Cutaneous localization of the membrane attack complex in discoid and systemic lupus erythematosus,”N. Engl. J. Med., Feb. 1982, 306, 264-270.
Bone, R.C., “Modulators of coagulation,”Arch. Intern. Med., Jul. 1992, 152, 1381-1389.
Carvalho, A.C., et al., “Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome,”J. Lab. Med., 1988, 112, 270-277.
Chavez-Cartaya, RE., et al., “Regulation of the complement cascade by soluble complement receptor type 1,”Transplantation, Apr. 15, 1995, 59(7), 1047-1052.
Chenoweth, D.E., et al., “Anaphylatoxin formation in extracorporeal circuits,”Complement, 1986, 3, 152-165.
Cochrane, C.G., “The role of complement in experimental disease models,”Springer Seminar Immunopathol., 1984, 7, 263-270.
Colman, R.W., “The role of plasma proteases in septic shock,”New Engl. J. Med., May 4, 1989, 320(18), 1207-1209.
Couser, W.G., et al., “Complement and the direct mediation of immune glomerular injury: a new perspective,”Kidney Inst., 1985, 28, 879-890.
Curran, D.P., et al., Stille couplings with fluorous tin reactants: attractive features for preparative organic synthesis and liquid-phase combinatorial synthesis,J. Org. Chem., 1996, 61(19), 6480-6481.
Dahl, M.V., et al., “Membrane attack complex of complement in dermatitis herpetiformis,”Arch. Dermatol., Jan. 1985, 121, 70-72.
Dahl, M.V., et al., “Deposition of the membrane attack complex of complement in bullous pemphigoid,”J. Invest. Dermatol., 1984, 82(2), 132-135.
Dai, C., et al., “The first general method for palladium-catalyzed negishi cross-coupling of aryl and vinyl chlorides: use of commercially available Pd(P9t-Bu)3)2as a catalyst,”J. Am. Chem. Soc., 2001, 123, 2719-2724.
Dell'Erba, C., et al., “A 13C N.M.R. study of 5-Cyano-, 5-Methoxycarbonyl-, 5-Carbamoyl-, and 5-Acetyl-3-nitro-2-X-thiophenes: substituent effects and their relation to the charge distribution in corresponding 2,2-dimethoxy meisenheimer adducts,”J. Chem. Soc., Perkins Trans., 1989, 2, 1779-1782.
Dell'Erba, C., et al., “Thiophene Series—VI* Substituent effect on the rate of nucleophilic substitution: kinetics of the reaction between 2-Bromo-3-Nitro-5-X-Thiophenes and piperidine in ethanol,”Tetrahedron, 1965, 21, 1061-1066.
Demling, R.H., et al., “The lung inflammatory response to thermal injury: relationship between physiologic and histologic changes,”Surgery, 1989, 106, 52-59.
Deppisch, R., et al., “Fluid phase generation of terminal complement complex as a novel index of bioincompatibility,”Kidney Inst., 1990, 37, 696-706.
Doyle, M.P., et al., “Alkyl nitrite—metal halide deamination reactions. 2. substitutive deamination of arylamines by alkyl nitrites and copper(II)halides. A direct and remarkably efficient conversion of arylamines to aryl halides,”J. Org. Chem., 1977, 42(14), 2426-2431.
Eisen, H.N., “An introduction to molecular and cellular principles of the immune responses,”Immunology, Harper & Row Publishers, Inc., Hager stown, MD, 1974, 512-525.
Falk, R.J., et al., “radioimmunoassay of the attack complex of complement in sera from patients with glomerulonephritis,”Clin. Research, 1984, 32(2), 503A (abstract).
Falk, R.J., et al., “Neoanigen of e polymerized nin omponen of omplemen,”J. Clin. Invest., Aug. 1983, 72, 560-573.
Fearon, D.T., “Ani-inflammatory and immunosuppressive effects of recombinant soluble complement receptors,”Clin. Exp. Immunol., 1991, 86(Suppl. 1), 43-46.
Feasby, T.E., et al., “Complement depletion suppresses Lewis rat experimental allergic neuritis,”Brain Res., 1987, 419, 97-103.
Field, L., et al., “Methylp-tolyl sulfone,”Organic Synthesis, John Wiley & Sons, 1963, vol. IV, 674-677.
Frost, C.G., et al., “Recent development in aromatic heteroatom coupling reactions,”J. Chem. Soc., Perkins Trans., 1998, 1, 2615-2623.
Gelfand, J.A., et al., “Alternative complement pathway activation increases mortality in a model of burn injury in mice,”J. Clin. Invest., Dec. 1982, 70, 1170-1176.
Guttman, R.D., “Genetics of acute rejection of rat cardiac allografts and a model of hyperacute rejection,”Transplantation, 1974, 17(4), 383-387.
Hack, C.E., et al., “Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis,”Am. J. Med., Jan. 1989, 86, 20-26.
Hazelton, C.J., et al., “2H-benzimidazoles (Isobenzimidazoles). Part 9.1Synthesis and reactions of 4,6-dibromo-2H-benzimidazole-2-spirocyclohexane,”Tetrahedron, 1995, 51(19), 5597-5608.
Hill, J., et al., “Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat,”J. Immunol., Sep. 1, 1992, 149(5), 1723-1728.
Ho, T.-L, et al., “Reduction of aromatic nitro compounds by titanium(III) chloride,”Synthesis, Jan. 1974, p. 45 (abstract).
Huang, J., et al., “Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein,”Science, Jul. 23, 1999, 285, 595-599.
Ishiyama, T., et al., “Palladium(0)-catalyzed cross-coupling reaction of alkoxydiboron with haloarenes: a direct procedure for arylboronic esters,”J. Org. Chem., 1995, 60, 7508-7510.
Jiang, G., et al., “GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6,”J. Med. Chem., 2001, 44, 453-467.
Kim, S., et al., 1,1'-thiocarbonyldi-2,2'-pyridone. A new useful reagent for functional group conversions under essentially neutral conditions,J. Org. Chem., 1986, 51, 2613-2615.
Knechtle, S.J., et al., “The effect of cyclosporine, total lympho
Ali Farah
Ballentine Shelley K.
Chen Jinsheng
Cummings Maxwell D.
Gushue Joan
3-Dimensional Pharmaceuticals Inc.
Ward Paul V.
Wilson James O.
LandOfFree
Thiophene amidines, compositions thereof, and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiophene amidines, compositions thereof, and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiophene amidines, compositions thereof, and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3546576